The study of BCMA-CD19 cCAR T Cell Treatment of Systemic Lupus Erythematosus

illustrative image

The company iCell Gene Therapeutics is commencing recruitment for the clinical trial of the BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE).

The condition is Relapsed/Refractory, Systemic Lupus Erythematosus (SLE).

A new clinical trial is recruiting patients in the following locations: China.

The trial officially began on the April 1, 2022 and is planned to complete on April 30, 2025.

iCAR Bio Therapeutics Ltd. China is the collaborator in this clinical trial.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05474885.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Предстоящие клинические испытания

The study of BCMA-CD19 cCAR T Cell Treatment of Systemic Lupus Erythematosus

All jobs

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться